Carcinoid Tumours

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 1997 Apr 1

PMID 9156122

Citations 5

Authors

S Janmohamed

S R Bloom

Affiliations

Soon will be listed here.

Abstract

The use of long-acting and potent somatostatin analogues is a major advance in the management of carcinoid tumours. In addition to providing effective symptom relief in malignant carcinoid syndrome, octreotide can also be used for diagnostic purposes. Despite its expense, octreotide is the current agent of choice for the treatment of this condition while analogues with different receptor specificities and pharmacokinetics hold promise for the future. Gastric carcinoids have aroused interest because of their experimental association with chronic hypergastrinaemia, a condition now commonplace because of the widespread use of H2-blockers and proton-pump inhibitors. This subject is reviewed. The slow evolution of many tumours demands prolonged follow-up and the active use of a variety of palliative interventions. These include measures such as hepatic and cardiac surgery, which might be deemed inappropriate for patients with other types of metastatic malignancy. Interferons may have a role when first-line treatments have failed. Chemotherapy is, generally, of limited value.

Citing Articles

Skeletal metastasis of carcinoid tumors: Two case reports and review of the literature.

Hori T, Yasuda T, Suzuki K, Kanamori M, Kimura T Oncol Lett. 2012; 3(5):1105-1108.

PMID: 22783400 PMC: 3389625. DOI: 10.3892/ol.2012.622.

From somatostatin to octreotide LAR: evolution of a somatostatin analogue.

Anthony L, Freda P Curr Med Res Opin. 2009; 25(12):2989-99.

PMID: 19842996 PMC: 3678951. DOI: 10.1185/03007990903328959.

Carcinoid heart disease: presentation, diagnosis, and management.

Fox D, Khattar R Heart. 2004; 90(10):1224-8.

PMID: 15367531 PMC: 1768473. DOI: 10.1136/hrt.2004.040329.

Carcinoid Heart Disease.

Di Luzio S , Rigolin Curr Treat Options Cardiovasc Med. 2000; 2(5):399-406.

PMID: 11096544 DOI: 10.1007/s11936-000-0035-9.

Carcinoid tumours.

Davies J, Green J, Currie C Postgrad Med J. 1998; 73(866):836.

PMID: 9497964 PMC: 2431541. DOI: 10.1136/pgmj.73.866.836.

References

Godwin 2nd J . Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975; 36(2):560-9. DOI: 10.1002/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4. View

Dharmsathaphorn K, Sherwin R, Cataland S, JAFFE B, Dobbins J . Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med. 1980; 92(1):68-9. DOI: 10.7326/0003-4819-92-1-68. View

MITTY H, Warner R, Newman L, Train J, PARNES I . Control of carcinoid syndrome with hepatic artery embolization. Radiology. 1985; 155(3):623-6. DOI: 10.1148/radiology.155.3.4001362. View

Kvols L, MOERTEL C, Oconnell M, SCHUTT A, Rubin J, Hahn R . Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986; 315(11):663-6. DOI: 10.1056/NEJM198609113151102. View

Duh Q, Hybarger C, Geist R, Gamsu G, Goodman P, Gooding G . Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg. 1987; 154(1):142-8. DOI: 10.1016/0002-9610(87)90305-9. View

Norheim I, Oberg K, Lindgren P, Lundqvist G, Magnusson A, Wide L . Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987; 206(2):115-25. PMC: 1493111. DOI: 10.1097/00000658-198708000-00001. View

Oberg K, Eriksson B . Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 1989; 28(3):425-31. DOI: 10.3109/02841868909111217. View

Vinik A, McLeod M, Fig L, Shapiro B, Lloyd R, Cho K . Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am. 1989; 18(4):865-96. View

Grander D, Oberg K, Lundqvist M, Janson E, Eriksson B, EINHORN S . Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990; 336(8711):337-40. DOI: 10.1016/0140-6736(90)91879-f. View

10.

Solcia E, Sessa F, Rindi G, Villani L, Riva C, Buffa R . Classification and histogenesis of gastroenteropancreatic endocrine tumours. Eur J Clin Invest. 1990; 20 Suppl 1:S72-81. DOI: 10.1111/j.1365-2362.1990.tb01781.x. View

11.

MOERTEL C, Kvols L, Oconnell M, Rubin J . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68(2):227-32. DOI: 10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i. View

12.

Lundin L . Carcinoid heart disease. A cardiologist's viewpoint. Acta Oncol. 1991; 30(4):499-502. DOI: 10.3109/02841869109092408. View

13.

Oberg K, Eriksson B . The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991; 79 Suppl 1:74-7. DOI: 10.1111/j.1365-2141.1991.tb08125.x. View

14.

Lamberts S, Krenning E, Reubi J . The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991; 12(4):450-82. DOI: 10.1210/edrv-12-4-450. View

15.

Ahlman H, Wangberg B, Nilsson O, Grimelius L, Granerus G, Modlin I . Aspects on diagnosis and treatment of the foregut carcinoid syndrome. Scand J Gastroenterol. 1992; 27(6):459-71. DOI: 10.3109/00365529209000106. View

16.

Basson M, Ahlman H, Wangberg B, Modlin I . Biology and management of the midgut carcinoid. Am J Surg. 1993; 165(2):288-97. DOI: 10.1016/s0002-9610(05)80529-x. View

17.

Marshall J, Bodnarchuk G . Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol. 1993; 16(2):123-9. View

18.

Kvols L, Reubi J . Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993; 32(2):197-201. DOI: 10.3109/02841869309083912. View

19.

Davila D, DUNN W, Tazelaar H, Pairolero P . Bronchial carcinoid tumors. Mayo Clin Proc. 1993; 68(8):795-803. DOI: 10.1016/s0025-6196(12)60641-7. View

20.

Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, Oei H . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8):716-31. DOI: 10.1007/BF00181765. View